Rare Lung Disease New Drug Set to Expand Patient Population by 7-Fold Amid Major Executive Profit Realization

On March 23, Insmed Incorporated (INSM), a developer of therapies for rare lung diseases, announced that its Phase 3b ENCORE trial of ARIKAYCE (amikacin liposome inhalation suspension) in newly diagnosed MAC lung disease patients met its primary endpoint of improved respiratory symptom scores. The study also demonstrated faster and more sustained sputum culture conversion compared with standard multidrug therapy, with a safety profile comparable to existing treatments. The company plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in the second half of 2026 to convert ARIKAYCE’s conditional approval into full approval and to file supporting data with Japan’s PMDA. If approved, the addressable patient population for refractory MAC in the U.S. and Japan could expand from about 30,000 to roughly 200,000. During the same period, Insmed’s general counsel and chief operating officer exercised stock options worth millions of dollars and sold all shares under a pre-established Rule 10b5-1 trading plan. The general counsel disclosed equity valued at about $3 million (₩4 billion), while the COO’s holdings were valued at approximately $32 million (₩43 billion).

On April 8, U.S. media reported that Insmed will discontinue the CEDAR Phase 2b trial of its DPP1 inhibitor, brensocatib, after the study failed to meet its primary endpoint, prompting a reshuffling of its development pipeline. In its February year-end financial report, the company had projected 2026 sales of at least $1 billion for BRINSUPRI and $450–470 million for ARIKAYCE, outlining its growth strategy for respiratory and rare disease assets.

Insmed, based in Bridgewater, New Jersey, is a global biopharmaceutical company focused on developing treatment options for patients with rare and severe respiratory diseases. Its lead products include ARIKAYCE for non-tuberculous mycobacterial lung disease and BRINSUPRI for chronic pulmonary conditions. Although diseases like MAC lung disease affect relatively small patient populations, they represent significant unmet medical needs, and ARIKAYCE has become one of the few inhaled antimicrobial therapies approved in the U.S. for MAC-related pulmonary disease.